ARCHIVES

Economic Analysis Finds Erlotinib Marginally Cost-Effective For NSCLC

This article is from The Cancer Letter archive.

Vol. 33 No. 2 | February 26, 2010

Download PDF Visit The Full Archive

Related Articles

ACS Initiates New Colorectal Cancer Screening Campaign

November 18, 1983

ODAC Endorses Tamoxifen Trial, With Modification to Ensure Enrollment of Women At Higher Risk

August 2, 1991

Next Bypass Budget: Slim, Trim, Modest

September 15, 1995

Data collection Completed In NCI Study of BRACA1

August 16, 1996

In Brief: Vietti Heads Chairman’s Committee; Chabner Seeks Deputy Candidates; WHO Centers At MSK

December 2, 1988

JRB Wins $3.6 Million Support contract

November 29, 1974